No Data
Yangpu Healthcare: Report for the third quarter of 2024
improve medical instruments (300030.SZ) released performance for the first three quarters, with a net loss of 42.5176 million yuan.
Improve medical instruments (300030.SZ) released the third quarter report for 2024, the company's revenue for the first three quarters was 4...
Improve medical instruments (300030.SZ): a net loss of 42.5176 million yuan in the first three quarters.
On October 25, improve medical instruments (300030.SZ) released the third quarter report for the year 2024, with the company achieving revenue of 0.421 billion yuan in the first three quarters, a decrease of 10.78% year-on-year; the net income attributable to shareholders of the listed company was -42.5176 million yuan; the non-recurring profit and loss deducted from the net income attributable to shareholders of the listed company was -13.4899 million yuan; with basic earnings per share of -0.14 yuan.
The medical instruments sector of the A-share market is declining, and Improve Medical Instruments has hit the limit down.
On September 18th, Intco Medical Technology and Improve Medical Instruments both hit the limit down, with Guanhao Biotech, Zhonghong Medical, Huada Intelligent Creation, Beijing Leadman Biochemistry and other companies leading the decline.
Improve Medical Instruments (300030.SZ): Currently, the main products are vacuum blood collection systems, not involving foreign medical investment or hospital investment
Gelonghui September 12th | Improve medical instruments (300030.SZ) accepted investor research on September 12, 2024, regarding 'Currently, the country has opened up foreign medical investment, hospital investment, what impact does this have on your company? As the major shareholder, what development suggestions does Geli have?'. The company stated that its main products are vacuum blood collection systems, and do not involve foreign medical investment or hospital investment.
Express News | Improve Medical Instruments: There is no new progress in the investigation of the detained chairman. The business of the subsidiary does not involve human stem cells.
No Data
No Data